LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Next-Generation Drugs Circumvent Adverse Immune Response

By Gerald M. Slutzky, PhD
Posted on 13 Dec 2016
Print article
Image: An artist’s rendering that depicts troublesome antibodies (purple Ys) attacking conventional PEGylated drugs while ignoring the modified version (Photo courtesy of Stacey Qi, Duke University).
Image: An artist’s rendering that depicts troublesome antibodies (purple Ys) attacking conventional PEGylated drugs while ignoring the modified version (Photo courtesy of Stacey Qi, Duke University).
Drugs conjugated with a modified type of polyethylene glycol (PEG)-based polymer demonstrate enhanced and longer life performance without triggering an immune response from indigenous anti-PEG antibodies.

The delivery of peptide and protein drugs is often complicated by short half-lives and the consequent need for frequent injections that limit efficacy, reduce patient compliance, and increase treatment cost.

PEG polymers have been attached to drugs to slow the body's clearing of them from the bloodstream, greatly lengthening the duration of their effects. However, the pervasiveness of PEG in daily human life has caused many people to develop antibodies to the polymer that result in adverse allergic responses to PEGylated drugs.

Investigators at Duke University (Durham, NC, USA) have addressed this problem by conjugating drugs to a modified form of PEG: poly[oligo(ethylene glycol) methyl ether methacrylate] or POEGMA. They reported in the November 28, 2016, online edition of the journal Nature Biomedical Engineering that a single subcutaneous injection of site-specific (C-terminal) conjugates of exendin-4 (exendin) - a therapeutic peptide that is clinically used to treat type II diabetes mellitus - and POEGMA with precisely controlled molecular weights lowered blood glucose for up to 120 hours in fed mice.

The investigators also showed that an exendin-C-POEGMA conjugate with an average of nine side-chain ethylene glycol (EG) repeats exhibited significantly lower reactivity towards patient-derived anti-poly(ethylene glycol) (anti-PEG) antibodies than two [US] Food and Drug Administration-approved PEGylated drugs, and that reducing the side-chain length to three EG repeats completely eliminated PEG antigenicity without compromising in vivo efficacy.

"We started down a path to make PEG-like conjugates of protein drugs more efficiently and stumbled into the PEG antigenicity problem," said senior author Dr. Ashutosh Chilkoti, professor of biomedical engineering at Duke University. "This work has been an interesting journey with the unexpected twists and turns that makes research so rewarding."

Related Links:
Duke University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more